| Dr James Antwi Owusu, MD | |
|
1120 Medical Plaza Dr, Shenandoah, TX 77380-3242 | |
| (713) 486-5000 | |
| Not Available |
| Full Name | Dr James Antwi Owusu |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 15 Years |
| Location | 1120 Medical Plaza Dr, Shenandoah, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942443312 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virginia Hospital Center | Arlington, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Mid-atlantic States,inc | 3779495858 | 1673 |
News Archive
The editors of the New England Journal of Medicine have raised concern regarding the cholesterol-lowering drugs Zetia and Vytorin.
A detailed report, available on the preprint server medRxiv*, describes the various facets of the second wave that set it apart from the first. The report also contains the findings of an extended SIR model that explored the potential effects of intervention at various time points in the second wave.
Research from Malawi, Birmingham and Liverpool has renewed hope that an effective vaccine could be developed against nontyphoidal strains of Salmonella. The work, funded by the Wellcome Trust and GlaxoSmithKline, suggests that the body's immune system could be primed to tackle even the most resilient of strains.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
› Verified 3 days ago
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20040102000644 |
News Archive
The editors of the New England Journal of Medicine have raised concern regarding the cholesterol-lowering drugs Zetia and Vytorin.
A detailed report, available on the preprint server medRxiv*, describes the various facets of the second wave that set it apart from the first. The report also contains the findings of an extended SIR model that explored the potential effects of intervention at various time points in the second wave.
Research from Malawi, Birmingham and Liverpool has renewed hope that an effective vaccine could be developed against nontyphoidal strains of Salmonella. The work, funded by the Wellcome Trust and GlaxoSmithKline, suggests that the body's immune system could be primed to tackle even the most resilient of strains.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
› Verified 3 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
The editors of the New England Journal of Medicine have raised concern regarding the cholesterol-lowering drugs Zetia and Vytorin.
A detailed report, available on the preprint server medRxiv*, describes the various facets of the second wave that set it apart from the first. The report also contains the findings of an extended SIR model that explored the potential effects of intervention at various time points in the second wave.
Research from Malawi, Birmingham and Liverpool has renewed hope that an effective vaccine could be developed against nontyphoidal strains of Salmonella. The work, funded by the Wellcome Trust and GlaxoSmithKline, suggests that the body's immune system could be primed to tackle even the most resilient of strains.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
› Verified 3 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Ambulatory Surgical Center |
| Entity Identifiers | NPI Number: 1366781700 PECOS PAC ID: 3779495858 Enrollment ID: O20130507000207 |
News Archive
The editors of the New England Journal of Medicine have raised concern regarding the cholesterol-lowering drugs Zetia and Vytorin.
A detailed report, available on the preprint server medRxiv*, describes the various facets of the second wave that set it apart from the first. The report also contains the findings of an extended SIR model that explored the potential effects of intervention at various time points in the second wave.
Research from Malawi, Birmingham and Liverpool has renewed hope that an effective vaccine could be developed against nontyphoidal strains of Salmonella. The work, funded by the Wellcome Trust and GlaxoSmithKline, suggests that the body's immune system could be primed to tackle even the most resilient of strains.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James Antwi Owusu, MD 6431 Fannin St, Msb 5.036, Houston, TX 77030-1501 Ph: (713) 500-5410 | Dr James Antwi Owusu, MD 1120 Medical Plaza Dr, Shenandoah, TX 77380-3242 Ph: (713) 486-5000 |
News Archive
The editors of the New England Journal of Medicine have raised concern regarding the cholesterol-lowering drugs Zetia and Vytorin.
A detailed report, available on the preprint server medRxiv*, describes the various facets of the second wave that set it apart from the first. The report also contains the findings of an extended SIR model that explored the potential effects of intervention at various time points in the second wave.
Research from Malawi, Birmingham and Liverpool has renewed hope that an effective vaccine could be developed against nontyphoidal strains of Salmonella. The work, funded by the Wellcome Trust and GlaxoSmithKline, suggests that the body's immune system could be primed to tackle even the most resilient of strains.
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
› Verified 3 days ago
Luis Daniel Neve, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 17183 Interstate 45 S Ste 690, Shenandoah, TX 77385 Phone: 936-270-4010 | |
Dr. William Marshall Guy, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 128 Vision Park Blvd, Suite 150, Shenandoah, TX 77384 Phone: 832-956-1040 Fax: 832-956-1045 | |
Ryan Eric Neilan, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 9301 Pincecroft Dr, Ste 150, Shenandoah, TX 77380 Phone: 281-362-1368 Fax: 281-364-8211 | |
Emily Tignor Patton, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 106 Vision Park Blvd, Shenandoah, TX 77384 Phone: 713-442-1800 | |
Rance W. Raney, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 9301 Pinecroft Dr, Ste 150, Shenandoah, TX 77380 Phone: 281-362-1368 Fax: 281-364-8211 | |
Donald E Newland, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 9301 Pinecroft Dr, Ste 150, Shenandoah, TX 77380 Phone: 281-362-1368 Fax: 281-364-8211 | |
Daniel A Strigenz, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 17183 Interstate 45 S Ste 690, Shenandoah, TX 77385 Phone: 936-270-4010 |